Preclinical aspects of lamivudine and famciclovir against hepatitis B virus

Journal of Viral Hepatitis

Volumn 6, Issue 2, 1999, Pages 89-106

  Shaw, T ^a   Locarnini, S A ^a  

^a VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

Author keywords

Antiviral chemotherapy; Hepatitis B; Lamivudine; Nucleoside; Penciclovir

Indexed keywords

ACICLOVIR; DEOXYCYTIDINE; DEOXYGUANOSINE; FAMCICLOVIR; GANCICLOVIR; LAMIVUDINE; NUCLEOSIDE ANALOG; PENCICLOVIR; ZALCITABINE;

ANTIVIRAL ACTIVITY; CHRONIC DISEASE; DEACETYLATION; DRUG CONFORMATION; DRUG EFFICACY; DRUG OXIDATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TRANSFORMATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; NUCLEOTIDE METABOLISM; PHOSPHORYLATION; PRIORITY JOURNAL; REVIEW;

2-AMINOPURINE; ANTIVIRAL AGENTS; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE;

EID: 0033014427     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.1999.00151.x     Document Type: Review

References (122)

1. Lok ASF. Treatment of chronic hepatitis B. J Viral Hep 1994; 1: 105-124.
2. Shaw T, Locarnini S. Hepatic purine and pyrimidine metabolism: implications for antiviral chemotherapy of viral hepatitis. Liver 1995; 15: 169-184.
3. Honkoop P, Scholte HR, de Man RA, Schalm SW. Mitochondrial injury. Lessons from the fialuridine trial. Drug Safety 1997; 17: 1-7.
4. Nassal M, Schaller H. Hepatitis B virus replication - an update. J Viral Hep 1996; 3: 217-226.
5. Sommadossi J-P. Treatment of hepatitis B by nucleoside analogs: still a reality. Curr Opin Infect Dis 1994; 7: 678-682.
6. Meuth M. The molecular basis of mutations induced by deoxyribonucleoside triphosphate pool imbalances in mammalian cells. Exp Cell Res 1989; 181: 305-311.
7. Griffith DA, Jarvis SM. Nucleoside and nucleobase transport systems of mammalian cells. Biochim Biophys Acta 1996; 1286: 153-181.
8. Arner ES, Eriksson S. Mammalian deoxyribonucleoside kinases. Pharmacol Ther 1995; 67: 155-186.
9. +-dependent nucleoside transport in liver: two different isoforms from the same gene family are expressed in liver cells. Biochem J 1998; 330: 997-1001.
10. Johansson M, Brismar S, Karlsson A. Human deoxycytidine kinase is located in the cell nucleus. Proc Natl Acad Sci USA 1997; 94: 11941-11945.
11. Johansson M, Karlsson A. Cloning of the cDNA and chromosomal location of the gene for human thymidine kinase 2. J Biol Chem 1997; 272: 8454-8458.
12. Johansson M, Karlsson A. Cloning and expression of human deoxyguanosine kinase cDNA. Proc Natl Acad Sci USA 1996; 93: 7258-7262.
13. Wang L, Hellman U, Eriksson S. Cloning and expression of human mitochondrial deoxyguanosine kinase cDNA. FEBS Lett 1996; 390: 39-43.
14. Harrison PT, Thompson R, Davison AJ. Evolution of herpesvirus thymidine kinase from cellular deoxycytidine kinase. J Gen Virol 1991; 72: 2583-2586.
15. Eriksson S, Kierdaszuk B, Munch-Petersen B, Oberg B, Johansson NG. Comparison of the substrate specificities of human thymidine kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogs. Biochem Biophys Res Commun 1991; 176: 586-592.
16. Verri A, Focher F, Priori G et al. Lack of enantiospecificity of human 2′-deoxycytidine kinase: relevance for the activation of beta-L-deoxycytidine analogs as antineoplastic and antiviral agents. Mol Pharmacol 1997; 51: 132-138.
17. Sjoberg AH, Wang L, Eriksson S. Substrate specificity of human recombinant mitochondrial deoxyguanosine kinase with cytostatic and antiviral purine and pyrimidine analogs. Mol Pharmacol 1998; 53: 270-273.
18. Spadari S, Ciarrochi G, Focher A et al. 5-iodo-2′-deoxy-L-uridine and (E)-5-(2-bromovinyl)2′-deoxy-L-uridine: selective phosphorylation by herpes simplex virus type 1 thymidine kinase, antiherpetic activity and cytotoxicity studies. Mol Pharmacol 1995; 47: 1231-1238.
19. Verri A, Priori G, Spadari S, Tondelli L, Focher F. Relaxed enantiselectivity of human mitochondrial thymidine kinase and chemotherapeutic uses of L-nucleoside analogues. Biochem J 1997; 328: 317-320.
20. Bennett LL, Allan PW, Arnett G et al. Metabolism in human cells of the D and L enantiomers of the carbocyclic analog of 2′-deoxyguanosine: substrate activity with deoxycytidine kinase, mitochondrial deoxyguanosine kinase, and 5′-nucleotidase. Antimicrob Agents Chemother 1998; 1045-1051.
21. Brady WA, Kokoris MS, Fitzgibbon M, Black ME. Cloning, characterization, and modeling of mouse and human guanylate kinases. J Biol Chem 1996; 271: 16734-16740.
22. Lu Q, Inouye M. Adenylate kinase complements nucleoside diphosphate kinase deficiency in nucleotide metabolism. Proc Natl Acad Sci USA 1996; 93: 5720-5725.
23. Huang SH, Tang A, Drisco B et al. Human dTMP kinase: gene expression and enzymatic activity coinciding with cell cycle progression and cell growth. DNA Cell Biol 1994; 13: 461-471.
24. Dopheide TA, Azad AA. The hepatitis B virus X protein is a potent AMP kinase. J Gen Virol 1996; 77: 173-176.
25. Mesnildrey S, Agou F, Karlsson A, Bonne DD, Veron M. Coupling between catalysis and oligomeric structure in nucleoside diphosphate kinase. J Biol Chem 1998; 273: 4436-4442.
26. Schaertl S, Konrad M, Geeves MA. Substrate specificity of human nucleoside-diphosphate kinase revealed by transient kinetic analysis. J Biol Chem 1998; 273: 5662-5669.
27. Bourdais J, Biondi R, Sarfati S et al. Cellular phosphorylation of anti-HIV nucleosides. Role of nucleoside diphosphate kinase. J Biol Chem 1996; 271: 7887-7890.
28. Frederiks WM, Bosch KS, Van Gulik R. A quantitative histochemical procedure for the demonstration of purine nucleoside phosphorylase activity in rat and human liver using Tetranitro BT and xanthine oxidase as auxiliary enzyme. Histochem J 1993; 25: 86-91.
29. Smith LH. Pyrimidine metabolism in man. N Engl J Med 1973; 238: 764-771.
30. Giorgelli F, Bottai C, Mascia L, Scolozzi C, Camici M, Ipata PL. Recycling of alpha-D-ribose 1-phosphate for nucleoside interconversion. Biochim Biophys Acta 1997; 1335: 6-22.
31. Valerio D, McIvor RS, Williams SR et al. Cloning of human adenosine deaminase cDNA and expression in mouse cells. Gene 1984; 31: 147-153.
32. Laliberte J, Momparler-RL. Human cytidine deaminase: purification of enzyme, cloning, and expression of its complementary DNA. Cancer Res 1994; 54: 5401-5407.
33. Ito S, Iwasaki A, Mizobuchi M, Matsuda Y. Purification of human liver guanase and characterization of antibody against it by immunoblotting. Clin Biochem 1990; 23: 113-120.
34. Misumi Y, Ogata S, Hirose S, Ikehara Y. Primary structure of rat liver 5′-nucleotidase deduced from the cDNA. J Biol Chem 1990; 265: 2178-2183.
35. Pesi R, Turriani M, Allegrini S et al. The bifunctional cytosolic 5′-nucleotidase: regulation of the phosphotransferase and nucleotidase activities. Arch Biochem Biophys 1994; 312: 75-80.
36. Keller PM, McKee SA, Fyfe JA. Cytoplasmic 5′-nucleotidase catalyses acyclovir phosphorylation. J Biol Chem 1985; 260: 8664-8667.
37. Ganem D, Pollack JR, Tavis J. Hepatitis B virus reverse transcriptase and its many roles in hepadnaviral genome replication. Infect Agents Dis 1994; 3: 85-93.
38. Zoulim F, Seeger C. Replication in hepatitis B viruses is primed by a tyrosine residue of the polymerase. J Virol 1994; 68: 6-13.
39. Focher F, Maga G, Bendiscioli A et al. Stereospecificity of human DNA polymerases α, β, γ, and ε, HIV reverse transcriptase, HSV-1 DNA polymerase, calf thymus terminal transferase and Escherichia coli DNA polymerase I in recognizing D- and L- thymidine 5′-triphosphate as substrate. Nucl Acids Res 1995; 23: 2840-2847.
40. Davis MG, Wilson JE, VanDraanen NA et al. DNA polymerase activity of hepatitis B virus particles: differential inhibition by L-enantiomers of nucleotide analogs. Antiviral Res 1996; 30: 133-145.
41. Boyd MR, Safrin S, Kern ER. Penciclovir: a review of spectrum of activity, selectivity, and cross-resistance. Antiviral Chem Chemother 1993; 4 (suppl 1): 4-11.
42. Vere Hodge RA, Sutton D, Boyd MR, Harnden MR, Jarvest RL. Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine; penciclovir]. Antimicrob Agents Chemother 1989; 33: 1765-1773.
43. Vere Hodge RA. Famciclovir and penciclovir. The mode of action of famciclovir including its conversion to penciclovir. Antiviral Chem Chemother 1993; 4: 67-84.
44. Perry CM, Wagstaff AJ. Famciclovir. A review of its pharmacological properties and therapeutic efficacy in herpesvirus infections. Drugs 1995; 50: 396-415.
45. Locarnini SA, Guo K, Lucas CR, Gust ID. Inhibition of HBV DNA replication by ganciclovir in patients with AIDS. Lancet 1989; 2: 1225-1226.
46. Wang Y, Bowden S, Shaw T et al. Inhibition of duck hepatitis B virus replication in vivo by the nucleoside analogue ganciclovir (9-[2-hydroxy-1-(hydroxymethyl) ethoxymethyl guanine. Antiviral Chem Chemother 1991; 2: 107-114.
47. Shaw T, Amor P, Civitico G, Boyd M, Locarnini S. In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus. Antimicrob Agents Chemother 1994; 38: 719-723.
48. Lin E, Luscombe C, Wang YY, Shaw T, Locarnini S. The guanine nucleoside analog penciclovir is active against chronic duck hepatitis B virus infection in vivo. Antimicrob Agents Chemother 1996; 40: 413-418.
49. Lin E, Luscombe C, Wang YY, Colledge D, Locarnini S. Long term therapy with penciclovir controls chronic duck hepatitis B virus infection in vivo. Antimicrob Agents Chemother 1998; 42: 2132-2137.
50. Tsiquaye KN, Slomka MJ, Maung M. Oral famciclovir against duck hepatitis B virus replication in hepatic and nonhepatic tissues of ducklings infected in ovo. J Med Virol 1994; 42: 306-310.
51. Tsiquaye KN, Sutton D, Maung M, Boyd M. Antiviral properties and pharmacokinetics of penciclovir and famciclovir in Pekin ducks chronically infected with duck hepatitis B. Antiviral Chem Chemother 1994; 7: 153-159.
52. Korba BE, Boyd MR. Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells. Antimicrob Agents Chemother 1996; 40: 1282-1284.
53. Main J, Brown JL, Howells Cet al. A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. J Viral Hep 1996; 3: 211-215.
54. Kruger M, Tillmann HL, Trautwein C et al. Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: a pilot study. Liver Transpl Surg 1996; 4: 253-262.
55. Singh N, Gayowski T, Wannstedt CF, Wagener MM, Marino IR. Pretransplant famciclovir as prophylaxis for hepatitis B virus recurrence after liver transplantation. Transplantation 1997; 63: 1415-1419.
56. Filer CW, Ramji JV, Allen GD et al. Metabolic and pharmacokinetic studies following oral administration of famciclovir to the rat and dog. Xenobiotica 1995; 25: 477-490.
57. Gill KS, Wood MJ. The clinical pharmacokinetics of famciclovir. Clin Pharmacokinet 1996; 31: 1-8.
58. Fowles SE, Pratt SK, Laroche J, Prince WT. Lack of a pharmacokinetic interaction between oral famciclovir and allopurinol in healthy volunteers. Eur J Clin Pharmacol 1994; 46: 355-359.
59. Clarke SE, Harrell AW, Chenery RJ. Role of aldehyde oxidase in the in vitro conversion of famciclovir to penciclovir in human liver. Drug Metab Dispos 1995; 23: 251-254.
60. Rashidi MR, Smith JA, Clarke SE, Beedham C. In vitro oxidation of famciclovir and 6-deoxypenciclovir by aldehyde oxidase from human, guinea pig, rabbit, and rat liver. Drug Metab Dispos 1997; 25: 805-813.
61. Shaw T, Mok SS, Locarnini SA. Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir. Hepatology 1996; 24: 996-1002.
62. Kitos TE, Tyrrell DLJ. Intracellular metabolism of 2′,3′-dideoxynucleosides in duck hepatocyte primary cultures. Biochem Pharmacol 1995; 49: 1291-1302.
63. Smee DF. Interaction of 9-(1,3,-dihydroxy-2-propoxymethyl)guanine with cytosol and mitochondrial deoxyguanosine kinases: possible role in anticytomegalovirus activity. Mol Cell Biochem 1985; 69: 75-81.
64. Zimmermann A, Michel D, Pavic I et al. Phosphorylation of aciclovir, ganciclovir, penciclovir and S2242 by the cytomegalovirus UL97 protein: a quantitative analysis using recombinant vaccinia viruses. Antiviral Res 1997; 36: 35-12.
65. Dannaoui E, Trepo C, Zoulim F. Inhibitory effect of penciclovir-triphosphate on duck hepatitis B virus reverse transcription. Antiviral Chem Chemother 1997; 8: 38-46.
66. Ilsley DD, Lee S-H, Miller WH. Kuchta RD. Acyclic guanosine analogs inhibit DNA polymerases α, δ, and ε with very different potencies and have unique mechanisms of action. Biochemistry 1995; 34: 2504-2510.
67. Famvir product information. SmithKline Beecham (International) Pty., Ltd., 1996.
68. Thust R, Schacke M, Wutzler P. Cytogenetic genotoxicity of antiherpes virostatics in Chinese hamster V79-E cells. I. Purine nucleoside analogues. Antiviral Res 1996; 31: 105-113.
69. Haynes P, Lambert TR, Mitchell ID. Comparative in-vivo genotoxicity of antiviral nucleoside analogues; penciclovir, ganciclovir and the xanthine analogue, caffeine, in the mouse bone marrow micronucleus assay. Mutat Res 1996; 369: 65-74.
70. Greenberg ML, Alludeen HS, Herschfield MS. Metabolism, toxicity, and anti-HIV activity of 2′-deoxy-3′-thiacytidine (BCH 189) in T and B cell lines. Ann NY Acad Sci 1990; 616: 517-518.
71. Coates JA, Cammack N, Jenkinson HJ et al. (-)-2′-deoxy-3′-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrob Agents Chemother 1992; 36: 733-739.
72. Hart GJ, Orr DC, Penn CR et al. Effects of (-)-2′-deoxy-3′-thiacytidine (3TC) 5′-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma. Antimicrob Agents Chemother 1992; 36: 1688-1694.
73. Pluda JM, Cooley TP, Montaner JS et al. A phase I/II study of 2′-deoxy-3′-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection. J Infect Dis 1995; 171: 1438-1447.
74. Rogan MM, Drake C, Goodall DM, Altria KD. Enantioselective enzymatic biotransformation of 2′-deoxy-3′-thiacytidine (BCH 189) monitored by capillary electrophoresis. Anal Biochem 1993; 208: 343-347.
75. Mahmoudian M, Baines BS, Drake CS et al. Enzymatic production of optically pure (2′R-cis)-2′-deoxy-3′-thiacytidine (3TC, lamivudine): a potent anti-HIV agent. Enzyme Microb Technol 1993; 15: 749-755.
76. Perry CM, Faulds D. Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. Drugs 1997; 53: 657-680.
77. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci USA 1991; 88: 8495-8499.
78. Chang C-N, Doong S-L, Zhou JH et al. Deoxycytidine deaminase-resistant stereoisomer is the active form of (±)-2′,3′-dideoxy-3′-thiacytidine in the inhibition of hepatitis B virus replication. J Biol Chem 1992; 267: 13938-13942.
79. Tyrell DLJ, FisherK, Cameron J. 2′,3′-dideoxy-3′-thiacytidine (Lamivudine) treatment of chimpanzees chronically infected with hepatitis B virus (HBV) resulted in a rapid suppression of HBV DNA in sera (abstr 228). Program and abstracts of the 18th International Symposium on Viral Hepatitis and Liver Diseases. Tokyo: Viral Hepatitis Research Foundation of Japan, 1993; p. 156.
80. Benhamou Y, Dohin E, Lunel-Fabiani F et al. Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients. Lancet 1995; 345: 396-397.
81. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333: 1657-1661.
82. Honkoop P, de Man RA, Zondervan PE, Schalm SW. Histological improvement in patients with chronic hepatitis B virus infection treated with lamivudine. Liver 1997; 17: 103-106.
83. Nevens F, Main J, Honkoop P et al. Lamivudine therapy for chronic hepatitis B: a six-month randomised dose-ranging study. Gastroenterology 1997; 113: 1258-1263.
84. Bain VG, Kneteman NM, Ma MM et al. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation. Transplantation 1996; 62: 1456-1462.
85. Al Faraidy K, Yoshida EM, Davis JE, Vartanian RK, Anderson FH, Steinbrecher UP. Alteration of the dismal natural history of fibrosing cholestatic hepatitis secondary to hepatitis B virus with the use of lamivudine. Transplantation 1997; 64: 926-928.
86. Morris DM, Selinger K. Determination of 2′-deoxy-3′-thiacytidine (3TC) in human urine by liquid chromatography: direct injection with column switching. J Pharm Biomed Anal 1994; 12: 255-264.
87. Zhou XJ, Sommadossi JP. Rapid quantitation of (-)-2′-deoxy-3′-thiacytidine in human serum by high-performance liquid chromatography with ultraviolet detection. J Chromatorg B 1997; 691: 417-424.
88. Blaney SM, Daniel MJ, Harker AJ, Godwin K, Balis FM. Pharmacokinetics of lamivudine and BCH-189 in plasma and cerebrospinal fluid of nonhuman primates. Antimicrob Agents Chemother 1995; 39: 2779-2782.
89. Rajagopalan P, Boudinot FD, Chu CK, Tennant BC, Baldwin BH, Schinazi RF. Pharmacokinetics of (-)-2′-3′-dideoxy-3′-thiacytidine in woodchucks. Antimicrob Agents Chemother 1996; 40: 642-645.
90. Hussey EK, Donn KH, Daniel MJ, Hall ST, Harker AJ, Evans GL. Interspecies scaling and pharmacokinetic parameters of 3TC in humans. J Clin Pharmacol 1994; 34: 975-977.
91. Yuen GJ, Morris DM, Mydlow PK, Haidar S, Hall ST, Hussey EK. Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine. J Clin Pharmacol 1995; 35: 1174-1180.
92. Plumb RS, Gray RD, Harker AJ, Taylor S. High-performance chromatographic assay for the sulphoxide metabolite of 2′-deoxy-3′-thiacytidine in human urine. J Chromatogr B 1996; 687: 457-461.
93. Heald AE, Hsyu PH, Yuen GJ, Robinson P, Mydlow P, Bartlett JA. Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction. Antimicrob Agents Chemother 1996; 40: 1514-1519.
94. Chang CN, Skalski V, Zhou JH, Cheng YC. Biochemical pharmacology of (+)- and (-)-2′,3′-dideoxy-3′-thiacytidine as anti-hepatitis B virus agents. J Biol Chem 1992; 267: 22414-22420.
95. Rahn JJ, Kieller DM, Tyrrell DL, Gati WP. Modulation of the metabolism of beta-L-(-)-2′,3′-dideoxy-3′-thiacytidine by thymidine, fludarabine, and nitrobenzylthioinosine. Antimicrob Agents Chemother 1997; 41: 918-923.
96. Cammack N, Rouse P, Marr CL et al. Cellular metabolism of (-) enantiomeric 2′-deoxy-3′-thiacytidine. Biochem Pharmacol 1992; 43: 2059-2064.
97. Gray NM, Marr CI, Penn CR, Cameron JM, Bethel RC. The intracellular phosphorylation of (-)-2′-deoxy-3′-thiacytidine (3TC) and the incorporation of 3TC 5′-monophosphate into DNA by HIV-1 reverse transcriptase and DNA polymerase gamma. Biochem Pharmacol 1995; 50: 1043-1051.
98. Kewn S, Veal GJ, Hoggard PG, Barry MG, Back DJ. Lamivudine (3TC) phosphorylation and drug interactions in vitro. Biochem Pharmacol 1997; 54: 589-595.
99. Shewach DS, Liotta DC, Schinazi RF. Affinity of the antiviral enantiomers of oxathiolane cytosine nucleosides for human 2′-deoxycytidine kinase. Biochem Pharmacol 1993; 45: 1540-1543.
100. Severini A, Liu XY, Wilson JS, Tyrrell DL. Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1995; 39: 1430-1435.
101. Fischer KP, Tyrrell D. Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine [(-)-beta-L-2′,3′-dideoxy-3′-thiacytidine] in vitro. Antimicrob Agents Chemother 1996; 40: 1957-1960.
102. Colledge D, Locarnini S, Shaw T. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology 1997; 26: 216-225.
103. Moraleda G, Saputelli J, Aldrich CE, Averett D, Condreay L, Mason WS. Lack of effect of antiviral therapy in non-dividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J Virol 1997; 71: 9392-9399.
104. Epivir (lamivudine) product information. Glaxo Wellcome Inc. Research Triangle Park, NC, USA, 1996.
105. Cui L, Schinazi RF, Gosselin G et al. Effect of beta-enantiomeric and racemic nucleoside analogues on mitochondrial functions in HepG2 cells. Implications for predicting drug hepatotoxicity. Biochem Pharmacol 1996; 52: 1577-1584.
106. Honkoop P, de Man RA, Scholte HR et al. Effect of lamivudine on morphology and function of mitochondria in patients with chronic hepatitis B. Hepatology 1997; 26: 211-215.
107. Back NKT, Nijhuis M, Keulen W et al. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J 1996; 15: 4040-4049.
108. Zeuzem S, de Man RA, Honkoop P, Roth WK, Schalm SW, Schmidt JM. Dynamics of hepatitis B virus infection in vivo. J Hepatol 1997; 27: 431-436.
109. Constrained evolution with respect to gene overlap in hepatitis B virus. J Mol Evol 1997; 44: 83-90.
110. Ling R, Mutimer D, Ahmed M et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 24: 711-713.
111. Honkoop P, Niesters HG, de Man RA, Osterhaus AD, Schalm SW. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J Hepatol 1997; 26: 1393-1395.
112. Bartholomew MM, Jansen RW, Jeffers LJ et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349: 20-22.
113. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24: 714-717.
114. Aye TT, Bartholomeusz AJ, Shaw T et al. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J Hepatol 1997; 26: 1148-1153.
115. Bartholomeusz A, Groenen LC, Locarnini S. Clinical experience with famciclovir against hepatitis B virus and development of resistance. Intervirology 1998; 40: 322-336.
116. Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998; 27: 628-633.
117. Fontana RJ, Lok ASF. Combination therapy for chronic hepatitis B. Hepatology 1997; 26: 234-237.
118. Korba BE. In vitro evaluation of combination therapies against hepatitis B virus replication. Antiviral Res 1996; 29: 49-51.
119. Tillmann HL, Trautwein C, Bock T et al. Response and mutations in patients sequentially treated with lamivudine and famciclovir for recurrent hepatitis B after liver transplantation. Hepatology 1997; 26 (suppl): 429A (abstr 1202).
120. Fagan EA, Lausch E, Rowell D et al. Improvement in protracted complicated hepatitis B with reduction in residual replication using lamivudine/famciclovir. Hepatology 1997; 26 (suppl): 504A (abstr 1502).
121. Honkoop P, de Man RA, Heijtink RA, Schalm SW. Hepatitis B reactivation after lamivudine. Lancet 1995; 346: 1156-1157.
122. Trepo C, Jezek P, Atkinson GF, Boon RJ. Efficacy of famciclovir in chronic hepatitis B: results of a dose finding study. Hepatology 1996; 24 (suppl): 188A (abstr 247).